MDT

100.13

+4.12%↑

A

136.65

-1.01%↓

VEEV

220.54

-0.41%↓

HQY

84.37

-0.86%↓

NEOG

9.44

+2.83%↑

MDT

100.13

+4.12%↑

A

136.65

-1.01%↓

VEEV

220.54

-0.41%↓

HQY

84.37

-0.86%↓

NEOG

9.44

+2.83%↑

MDT

100.13

+4.12%↑

A

136.65

-1.01%↓

VEEV

220.54

-0.41%↓

HQY

84.37

-0.86%↓

NEOG

9.44

+2.83%↑

MDT

100.13

+4.12%↑

A

136.65

-1.01%↓

VEEV

220.54

-0.41%↓

HQY

84.37

-0.86%↓

NEOG

9.44

+2.83%↑

MDT

100.13

+4.12%↑

A

136.65

-1.01%↓

VEEV

220.54

-0.41%↓

HQY

84.37

-0.86%↓

NEOG

9.44

+2.83%↑

Search

Charles River Laboratories International Inc

Abrir

SetorSaúde

220.37 1.18

Visão Geral

Variação de preço das ações

24h

Atual

Mín

216.72

Máximo

223.15

Indicadores-chave

By Trading Economics

Rendimento

2.9M

56M

Vendas

-27M

1B

EPS

2.43

Margem de lucro

5.529

Funcionários

18,700

EBITDA

-23M

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

-1.39% downside

Dividendos

By Dow Jones

Próximos Ganhos

18 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2B

11B

Abertura anterior

219.19

Fecho anterior

220.37

Sentimento de Notícias

By Acuity

45%

55%

140 / 361 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de jan. de 2026, 23:43 UTC

Conversa de Mercado

Gold Consolidates; May Face Technical Correction -- Market Talk

20 de jan. de 2026, 23:42 UTC

Conversa de Mercado

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 de jan. de 2026, 23:41 UTC

Ganhos

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 de jan. de 2026, 23:29 UTC

Conversa de Mercado

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 de jan. de 2026, 23:26 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de jan. de 2026, 23:26 UTC

Conversa de Mercado

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 de jan. de 2026, 22:45 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 de jan. de 2026, 22:45 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 de jan. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 de jan. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 de jan. de 2026, 22:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 de jan. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 de jan. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 de jan. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 de jan. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 de jan. de 2026, 22:18 UTC

Ganhos

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 de jan. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 de jan. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 de jan. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 de jan. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 de jan. de 2026, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 de jan. de 2026, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 de jan. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 de jan. de 2026, 22:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 de jan. de 2026, 22:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 de jan. de 2026, 22:06 UTC

Ganhos

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 de jan. de 2026, 22:00 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

ESG Roundup: Market Talk

20 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

-1.39% parte inferior

Previsão para 12 meses

Média 216.64 USD  -1.39%

Máximo 265 USD

Mínimo 170 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

9

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

140 / 361 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat